LON:OXB

Oxford Biomedica (OXB) Share Forecast, Price & News

GBX 469

+6.50 (+1.41%)

(As of 06/6/2023 ET)

Compare

Today's Range: 458.50
▼
469
50-Day Range: 401
▼
469
52-Week Range: 276.62
▼
575

Volume: 39,861 shs
Average Volume: 102,604 shs
Market Capitalization: £454.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: GBX 1,010

Profile Analyst Ratings Chart Competitors Insider Trades Headlines

About Oxford Biomedica (LON:OXB) Stock

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

OXB Stock News Headlines

May 26, 2023 | americanbankingnews.com

Oxford Biomedica (LON:OXB) Price Target Cut to GBX 1,010

May 25, 2023 | msn.com

RBC Capital Markets Reiterates Oxford Biomedica (LSE:OXB) Outperform Recommendation

June 6, 2023 | UNKNOWN (Ad)

The Stock That's Brining Lithium Back To America!

The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S Soil

May 15, 2023 | finance.yahoo.com

Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system

May 5, 2023 | finance.yahoo.com

Why Investors Shouldn't Be Surprised By Oxford Biomedica plc's (LON:OXB) Low P/S

April 26, 2023 | finance.yahoo.com

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

April 25, 2023 | markets.businessinsider.com

Oxford Biomedica Posts FY Loss

April 21, 2023 | marketwatch.com

2023-2030 "CGT CDMO Market" Share | Global Industry Analysis and Forecast

June 6, 2023 | UNKNOWN (Ad)

Lithium Has Boomed And This American Stock Is Ready..

Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!

April 12, 2023 | marketwatch.com

2023-2030 Global CGT CDMO Market is Growing Rapidly with Modern Trend

March 26, 2023 | marketwatch.com

CGT CDMO Market Share and Forecast till 2030

March 15, 2023 | benzinga.com

Oxford BioMedica Stock (OTC:OXBDF), Quotes and News Summary

March 11, 2023 | finance.yahoo.com

As Oxford Biomedica plc's market cap (LON:OXB) drops to UK£484m, insiders might be questioning their decision to buy earlier this year

February 25, 2023 | marketwatch.com

What is a CAGR of CGT CDMO Market? CGT CDMO Market Value in 2028 with Competition Analysis Data of Top Key Players

February 22, 2023 | marketwatch.com

CGT CDMO Market Size Global Research Report, 2023 - 2028

January 30, 2023 | marketwatch.com

CGT CDMO Market Size 2023 Trend and Opportunities, Analysis, CAGR and Value Chain Study, Business Growth to 2028

January 20, 2023 | marketwatch.com

CGT CDMO Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028

January 12, 2023 | marketwatch.com

CGT CDMO Market Present Development Scenario and Growth Prospects to help you understand the Implications for Your Business | Newest 112 Insights

January 1, 2023 | finance.yahoo.com

A Look At The Intrinsic Value Of Oxford Biomedica plc (LON:OXB)

December 14, 2022 | yahoo.com

Oxford Biomedica Solutions forms new partnerships with three biotechnology companies

December 9, 2022 | marketwatch.com

CGT CDMO Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028

November 22, 2022 | finance.yahoo.com

Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer

October 25, 2022 | marketwatch.com

CGT CDMO Market Size 2022 Is Changing Consumer Habits, this Industry in the Globe Has Noticed Substantial Growth to 2028 | 112 Pages Report

October 7, 2022 | finance.yahoo.com

Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree

September 29, 2022 | finance.yahoo.com

Bullish Oxford Biomedica plc (LON:OXB) insiders filled their treasuries with UK£658k worth of stock over last year

September 15, 2022 | finance.yahoo.com

Edited Transcript of OXB.L earnings conference call or presentation 15-Sep-22 12:00pm GMT

September 15, 2022 | uk.finance.yahoo.com

FTSE: Oxford Biomedica sees revenue drop as COVID vaccine demand drops

See More Headlines

OXB Price History

30 days | 90 days | 365 days | Advanced Chart

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:OXB
CUSIP: N/A
CIK: N/A
Web: www.oxfordbiomedica.co.uk
Phone: +44-1865-783000
Fax: N/A
Employees: 744
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: GBX 1,010
High Stock Price Forecast: GBX 1,010
Low Stock Price Forecast: GBX 1,010
Forecasted Upside/Downside: +115.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX (0.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-39,160,000.00
Net Margins: -27.97%
Pretax Margin: N/A
Return on Equity: -21.33%
Return on Assets: -8.33%

Debt

Debt-to-Equity Ratio: 48.38
Current Ratio: 3.61
Quick Ratio: 1.67

Sales & Book Value

Annual Sales: £139.99 million
Price / Sales: 3.25
Cash Flow: GBX 156 per share
Price / Cash Flow: 3.01
Book Value: GBX 213 per share
Price / Book: 2.20

Miscellaneous

Outstanding Shares: 96,960,000
Free Float: N/A
Market Cap: £454.74 million
Optionable: Not Optionable
Beta: 0.92

Key Executives

Dr. Roch Doliveux
Interim CEO & Chairman

Mr. Stuart Paynter (Age 49)
CFO, Company Sec. & Director
Comp: $755k

Mr. Nick Page
Chief Operations Officer

Dr. James Miskin Ph.D.
Chief Technical Officer

Dr. Kyriacos Mitrophanous Ph.D.
Chief Scientific Officer

Mr. Matthew Treagus
Chief Information Officer

Sophia Bolhassan
Head of Investor Relations

Ms. Natalie Louise Walter
Gen. Counsel

Dr. Jason Slingsby MBA
Chief Bus. & Corp. Devel. Officer

Ms. Sarah Macleod
Head of Communications

Key Competitors

View All Competitors

Insiders

Catherine Moukheibir
Bought 8,910 shares on 10/11/2022
Total: £2.82 M ($317.00/share)

View All Insider Transactions

OXB Stock - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OXB shares.
View OXB analyst ratings or view top-rated stocks.
What is Oxford Biomedica's stock price forecast for 2023?: 1 equities research analysts have issued 12 month price objectives for Oxford Biomedica's shares. Their OXB share price forecasts range from GBX 1,010 to GBX 1,010. On average, they predict the company's stock price to reach GBX 1,010 in the next year. This suggests a possible upside of 115.4% from the stock's current price.
View analysts price targets for OXB or view top-rated stocks among Wall Street analysts.
How have OXB shares performed in 2023?: Oxford Biomedica's stock was trading at GBX 442.50 on January 1st, 2023. Since then, OXB stock has increased by 6.0% and is now trading at GBX 469.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Oxford Biomedica own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).

What is Oxford Biomedica's stock symbol?: Oxford Biomedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."
How do I buy shares of Oxford Biomedica?: Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Oxford Biomedica's stock price today?: One share of OXB stock can currently be purchased for approximately GBX 469.
How much money does Oxford Biomedica make?: Oxford Biomedica (LON:OXB) has a market capitalization of £454.74 million and generates £139.99 million in revenue each year. The biopharmaceutical company earns £-39,160,000.00 in net income (profit) each year or GBX (0.42) on an earnings per share basis.
How many employees does Oxford Biomedica have?: The company employs 744 workers across the globe.
How can I contact Oxford Biomedica?: Oxford Biomedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The official website for the company is www.oxfordbiomedica.co.uk. The biopharmaceutical company can be reached via phone at +44-1865-783000.

This page (LON:OXB) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial